MacroGenics Files 8-K: Board and Executive Compensation Changes
Ticker: MGNX · Form: 8-K · Filed: Feb 26, 2025 · CIK: 1125345
Sentiment: neutral
Topics: management-change, executive-compensation, board-of-directors
Related Tickers: MGNX
TL;DR
MacGenics shakes up board, adjusts exec pay - filing shows changes effective Feb 25, 2025.
AI Summary
On February 25, 2025, MacroGenics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing indicates a departure of certain officers and the election of new directors, alongside updates to compensatory plans for key personnel.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy, governance, or financial outlook, impacting investor confidence and stock performance.
Risk Assessment
Risk Level: medium — Changes in board and executive roles can sometimes precede significant strategic shifts or indicate internal challenges, warranting closer investor scrutiny.
Key Numbers
- 001-36112 — SEC File Number (Identifies the company's filing history with the SEC.)
- 20850 — ZIP Code (Part of the company's principal executive office address.)
Key Players & Entities
- MACROGENICS, INC. (company) — Registrant
- February 25, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- Rockville, Maryland (location) — Address of Principal Executive Offices
FAQ
What specific roles have been affected by the departure of certain officers?
The filing does not specify the exact roles of the departing officers, only that there have been departures.
Who are the newly elected directors?
The filing does not name the newly elected directors.
What are the key changes in the compensatory arrangements for certain officers?
The filing mentions changes to compensatory arrangements but does not detail the specifics of these changes.
What is the exact date of the earliest event reported in this 8-K?
The earliest event reported is dated February 25, 2025.
What is the company's principal executive office address?
The company's principal executive office is located at 9704 Medical Center Drive, Rockville, Maryland 20850.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on February 26, 2025 regarding MACROGENICS INC (MGNX).